郭思治: 金活醫藥(01110.HK)多元拓展代理產品及分銷渠道 積極求變帶動增長
香港股票分析師協會副主席郭思治稱,金活醫藥(01110.HK)8月底公布了2022年中期業績,收入基本持平,約4.2億元人民幣(下同),公司擁有人應佔溢利卻按年大升24.3%,達至約2,421萬元。在2022年全球整體經濟下行、國際形勢及疫情反覆的雙重影響下,金活醫藥交出的這份業績增長相當不俗。
金活醫藥是全球知名大健康產品的渠道供應鏈領先企業,主要分為兩大業務:代理及分銷藥品及保健品,以及研發、製造及分銷醫療設備。金活醫藥以營運多個百年及國際著名中成藥產品的著名,例如星級產品京都念慈菴產品系列、喇叭牌正露丸、依葉酸片等。隨著金活醫藥於慢性疾病藥品的推廣模式愈見成熟,依葉牌馬來酸依那普利葉酸片2022年上半年銷售額較去年同期大幅增長300%。
此外,金活醫藥不斷拓展新的產品代理,引進了曼秀雷敦旗下樂敦瑩品牌等,同時,不斷豐富產品組合類別,例如康萃樂女性益生菌,又取得藻油領導品牌Life’sDHA的中國線上線下總代理權,包括旗艦店經營權﹑跨境線上及中國線下經銷權。期內,Life’sDHA銷售額較去年同期迅速增長213.2%,有望成為公司另一名星產品系列,為公司帶來增長動力。
去年3月,金活醫藥參股蘭州佛慈製藥股份有限公司的香港公司香港佛慈,並負責以香港佛慈為平台在港澳市場營運銷售佛慈系列中成藥產品。據瞭解,蘭州佛慈製藥股份有限公司1929年創建於上海,是中國有著近百年製藥歷史的「中華老字號」的企業。目前,金活醫藥於香港佛慈的營銷管道佈局已成形,產品覆蓋藥房數目由幾十家增至一百多家,佛慈產品銷售按年增長超過15%,表現甚佳。同時,金活醫藥與華潤堂深度合作,雙方合作的產品由以前2個品規漸增至16個品規,可見金活醫藥品牌擁有優質的行業信譽,核心競爭力強勁。
即便在全球整體經濟不穩的大環境下,金活醫藥仍積極求變。金活醫藥擁有成熟的產品評估體系以及高效的國際供應鏈體系,而且不斷擴大代理及分銷渠道,業績穩固增長,筆者看好金活醫藥的前景。醫藥板塊抗風險能力高,有意投資醫藥板塊的投資者不妨考慮金活醫藥。
(筆者為證監會持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.